Slideshow

Key Concepts About Polypharmacy in Psychotic Disorders

Author(s):

Jose M. Rubio, MD

Clinicians should keep in mind the risk-to-benefit ratio considerations before initiating polypharmacy, especially if they have patients with prescriptions inherited from several sources. Here: A summary of recommendations about the use of polypharmacy in psychotic disorders.

Related Videos
sc
schizophrenia
clozapine
brain
cognition
clock
clozapine
steering wheel
schizophrenia
Christoph U. Correll
Related Content
benzodiazepine
April 16th 2025

Benzodiazepine Discontinuation Associated With Increased Mortality in Patients on Stable, Long-Term Benzodiazepines

Geena Sutherland, MD Nancy Kartiko, MD Haley Schuster, MD Mark Mullen, MD Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP
Here's to a Psychedelic Revolution
April 9th 2022

Here's to a Psychedelic Revolution

Amir Inamdar MBBS, DNB (Psych), MFPM
road choice
April 15th 2025

The Slow Road to Psychosis

Husein Hijazi, MD Nidal Moukaddam, MD, PhD
Treating ‘Morally Objectionable’ Patients
September 27th 2021

Treating ‘Morally Objectionable’ Patients

James L. Knoll IV, MD
bipolar disorder
April 7th 2025

Online Survey Reveals Clinicians’ Top Concerns in BDI, Schizophrenia Treatment

Grace Koennecke
FDA
April 1st 2025

New NDA Submitted: Bysanti to Treat Acute Bipolar I and Schizophrenia

Leah Kuntz
© 2025 MJH Life Sciences

All rights reserved.